Macrogenics, Inc. share price logo

Macrogenics, Inc. Share Price

NASDAQ: MGNX

Small Cap

$2.92

-0.26

(-8.18%)

as on

Macrogenics, Inc. Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $2.85
    $3.19
    downward going graph

    2.40%

    Downside

    9.25%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.99
    $3.54
    downward going graph

    66.11%

    Downside

    21.23%

    Upside

    downward going graph

Macrogenics, Inc. share price movements today

Previous Close
$3.18
Open
$3.16
Volume
1.4M
Day's Low - High
$2.85 - $3.19
52 Week Low - High
$0.99 - $3.54

Macrogenics, Inc. Historical Returns

1 Month Return
+ 47.24 %
3 Month Return
+ 81.99 %
1 Year Return
+ 132.54 %
3 Year Return
-55.94 %
5 Year Return
-91.17 %

Macrogenics, Inc. Stock Fundamentals & Key Indicators

Check Macrogenics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$202.1M

EPS (TTM)

-1.725

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.70%

PE Ratio (TTM)

-1.6

Industry PE ratio

-4.397180327868853

PEG Ratio

0.01

EBITDA

-65.7M

Revenue (TTM)

149.5M

Profit Margin

-49.91%

Return On Equity TTM

-86.95%

Macrogenics, Inc. Stock Valuation

Track how Macrogenics, Inc. P/E has moved over time to understand its valuation trends.

Macrogenics, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-12.96x)

June 30, 2021

Industry (-4.40x)

March 28, 2026

Today (-1.60x)

March 28, 2026

Highest (-0.92x)

September 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.60x

Macrogenics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Macrogenics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Macrogenics, Inc. image
Macrogenics, Inc.
BUY$202.1M-91.17%-1.6-49.91%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.5B132.92%140.848.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.2B101.77%29.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.8BNA112.585.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.0B54.69%18.2531.41%

Stock Returns calculator for Macrogenics, Inc. Stock including INR - Dollar returns

The Macrogenics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Macrogenics, Inc. investment value today

Current value as on today

₹2,42,255

Returns

₹1,42,255

(+142.26%)

Returns from Macrogenics, Inc. Stock

₹1,31,746 (+131.75%)

Dollar Returns*

₹10,509 (+10.51%)

Analyst Recommendation on Macrogenics, Inc. Stock

Based on 18 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 18 analysts, 88.89% of analysts recommend a 'BUY' rating for Macrogenics, Inc.. Average target price of $3.6

Macrogenics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Macrogenics, Inc..

What analysts predicted

18.89%UPSIDE

Target Price

$3.6

Current Price

$2.92

Analyzed by

18 Analysts

Target

$3.60

Macrogenics, Inc. target price $3.6, a slight upside of 18.89% compared to current price of $2.92. According to 18 analysts rating.

Macrogenics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Macrogenics, Inc. Stock has increased by 87% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:87% versus previous 30 day period

Macrogenics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
10
10
9
10
110
17
13
22
72
41
Gross Profit
10
-36
6
7
68
12
7
13
59
25
Operating Income
-35
-49
-53
-58
54
-52
-42
-36
18
-12
EBITDA
19
-47
-49
-53
56
-12
-39
-33
21
-15
Interest Expense
-
2
1
0
-
0
0
0
3
4
Depreciation
1
1
1
1
1
2
1
1
1
1
Income Before Tax
17
-46
-52
-55
56
-14
-41
-36
16
-14
Income Tax Expense
-1
3
1
-
-1
0
-
0
-
0
Net Income
17
-46
-52
-55
56
-15
-41
-36
16
-14
Net Profit Margin
168.84%
-429.78%
-573.26%
-515.55%
50.86%
-86.98%
-311.07%
-162.99%
23.09%
-34.33%

Macrogenics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
86
155
60
62
97
75
151
57
148
149
Gross Profit
86
155
60
62
97
72
144
48
136
106
Operating Income
-60
-22
-171
-177
-131
-202
-121
-168
-110
-72
EBITDA
-52
-14
-162
-164
-119
-191
-109
2
-57
-65
Interest Expense
-
-
-
-
-
0
0
1
1
8
Depreciation
-
7
8
10
11
11
11
9
7
7
Income Before Tax
-58
-19
-171
-151
-129
-202
-119
-9
-66
-75
Income Tax Expense
-7
-7
0
10
-11
-11
0
9
0
0
Net Income
-58
-19
-171
-151
-117
-190
-120
-9
-66
-74
Net Profit Margin
-67.60%
-12.62%
-285.18%
-244.76%
-120.48%
-252.31%
-78.99%
-15.84%
-45.14%
-49.91%

Macrogenics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-46
-52
-55
56
-15
-41
-36
16
-14
Operating Cash Flow
-28
-45
-44
60
-38
-46
-46
-30
43
Investing Cash Flow
38
24
47
35
41
9
-37
-20
-65
Financing Cash Flow
0
0
0
0
0
0
69
-
0
Change in Cash
11
-20
3
95
3
-37
-14
-50
-22

Macrogenics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-19
-171
-151
-129
-202
-119
-9
-66
-74
Operating Cash Flow
14
-153
-134
-111
-143
-86
-78
-68
-81
Investing Cash Flow
77
56
-79
-7
-36
70
-80
149
-114
Financing Cash Flow
35
104
119
174
122
1
150
0
69
Change in Cash
127
8
-93
54
-57
-14
-7
81
-125

Global Institutional Holdings in Macrogenics, Inc.

Funds
Holdings
Armistice Capital, LLC
9.99%
Wasatch Advisors LP
2.82%
Two Sigma Advisers, LLC
1.89%
Citadel Advisors Llc
1.63%
Millennium Management LLC
3.35%
See all

Insights on Macrogenics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, MGNX stock has moved up by 11.2%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, MGNX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 74.0% return, outperforming this stock by 126.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 72.83M → 41.22M (in $), with an average decrease of 43.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 16.82M → -14.15M (in $), with an average decrease of 184.2% per quarter

About Macrogenics, Inc.

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
OrganisationMacrogenics, Inc.
Headquarters9704 Medical Center Drive, Rockville, MD, United States, 20850
IndustryHealth Technology
CEOMr. Eric Blasius Risser
E-voting on sharesClick here to vote

Key Management of Macrogenics, Inc.

Name

Title

Mr. James Karrels

Senior VP, CFO & Corporate Secretary

Dr. Thomas M. Spitznagel Ph.D.

Senior Vice President of Technical Operations

Mr. Harish Krishnaswamy

Senior Vice President of Business Development & Portfolio Planning

Dr. Frank George Perabo FEBU, M.D., Ph.D.

Vice President & Interim Head of Clinical Development

Ms. Beth Smith

VP, Controller & Treasurer

Mr. Eric Blasius Risser

CEO, President & Director

Dr. Ezio Bonvini M.D.

Senior VP of Research & Chief Scientific Officer

Mr. Jeffrey Stuart Peters J.D.

Senior VP, General Counsel & Corporate Compliance Officer

Mr. Steve Harig

Senior Vice President of Human Resources

FAQs

What is Macrogenics, Inc. share price today?

Macrogenics, Inc. share price today is $2.92 as on at the close of the market. Macrogenics, Inc. share today touched a day high of $3.19 and a low of $2.85.

What is the 52 week high and 52 week low for Macrogenics, Inc. share?

Macrogenics, Inc. share touched a 52 week high of $3.54 on and a 52 week low of $0.99 on . Macrogenics, Inc. stock price today i.e. is closed at $2.92,which is 17.51% down from its 52 week high and 195.05% up from its 52 week low.

What is Macrogenics, Inc.'s market capitalisation today?

Macrogenics, Inc. market capitalisation is $0.00T as on .

How to invest in Macrogenics, Inc. Stock (MGNX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Macrogenics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Macrogenics, Inc. Shares that will get you 0.5137 shares as per Macrogenics, Inc. share price of $2.92 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Macrogenics, Inc. Stock (MGNX) from India?

Indian investors can start investing in Macrogenics, Inc. (MGNX) shares with as little as ₹94.651 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.51 in Macrogenics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Macrogenics, Inc. share’s latest price of $2.92 as on March 28, 2026 at 1:29 am IST, you will get 3.4247 shares of Macrogenics, Inc.. Learn more about fractional shares .

What are the returns that Macrogenics, Inc. has given to Indian investors in the last 5 years?

Macrogenics, Inc. stock has given -91.17% share price returns and 29.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?